Abstracts Archive - Page 1945 of 2607 - ACR Meeting Abstracts

Abstract Number: 1109 • 2015 ACR/ARHP Annual Meeting
Co-Crystal Structure of TACI and APRIL-BAFF-BAFF Heteromer Suggests That Charged Residues in APRIL and BAFF Dictate Their Receptor Binding Affinities
Xuliang Jiang¹, Thomas Tan², Klaus Maskos³, Alfred Lammens³, Pascal Schneider⁴ and Wolf Palinksy⁵, ¹Research and Development Institute, EMD Serono, Billerica, MA, ²EMD Serono Research, Billerica, MD, ³Proteros Biostructures GmbH, Planegg, Germany, ⁴Biochemistry, University of Lausanne, Epalinges, Switzerland, ⁵Global Biotech Development, Merck Serono, Aubonne, Switzerland
Background/Purpose: The human B cell survival factor, B cell activation factor (BAFF), and its closely related homologue, a proliferation-inducing ligand (APRIL), modulate B cell functions…
Abstract Number: 1110 • 2015 ACR/ARHP Annual Meeting
A Proliferative Inducing Ligand (APRIL) Promotes IL-10 Production of Human B Cells
Charlotte Hua¹, Rachel Audo², Nataliya Yeremenko³, Dominique Baeten⁴, Michael Hahne², Bernard Combe⁵, Jacques Morel⁵ and Claire I. Daien⁵, ¹Department of Rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²IGMM-CNRS UMR5535, Montpellier, France, ³Academic medical center, University of Amsterdam, Amsterdam, France, ⁴1Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁵Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: B cells may have a negative regulatory role, mainly mediated by interleukin 10 (IL-10). We recently showed that regulatory B-cell functions are impaired in…
Abstract Number: 1111 • 2015 ACR/ARHP Annual Meeting
Relapse of Lupus after B-Cell Depletion Therapy Is Associated with Loss of Apoptotic Cell Clearance and Elevated Type I Interferon Responses in Lupus Prone BXD2
Hui-Chen Hsu^1,2, Zhaoqi Yan³, PingAr Yang², Qi Wu^1,2, Jennie Hamilton⁴, Jun Li⁵, Hao Li⁶, Bao Luo⁶, Laurie Harrington³ and John Mountz⁷, ¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Cell, Developmntl & Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷Dept of Med/Rheumatology Div, University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: B-cell depletion therapy (BCDT) is a promising therapy for autoimmune diseases but relapse can occur. In rheumatoid arthritis, patients who did not respond well…
Abstract Number: 1112 • 2015 ACR/ARHP Annual Meeting
Obinutuzumab Outperforms Rituximab at Inducing B-Cell Cytotoxicity in Vitro through Fc-Mediated Effector Mechanisms in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Venkat Reddy¹, Christian Klein², David A. Isenberg³, Geraldine Cambridge⁴, Martin Glennie⁵, Mark Cragg⁶ and Maria J. Leandro¹, ¹Rheumatology, University College London, London, United Kingdom, ²Roche Pharmaceutical Research & Early Development Oncology Discovery & Translational Area, Roche Glycart AG, Schlieren, Switzerland, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ⁴Rheumatology, Centre for Rheumatology and Bloomsbury Rheumatology Unit, University College London, London, United Kingdom, ⁵Antibody and Vaccine group, Southampton University, Southampton, United Kingdom, ⁶Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom
Background/Purpose: Obinutuzumab (OBZ, a Type II anti-CD20 monoclonal antibody [mAb] with afucosylated Fc portion and enhanced affinity for Fcγ receptor III) is more efficient than…
Abstract Number: 1113 • 2015 ACR/ARHP Annual Meeting
B Cell Signature Profiling in Systemic Lupus Erythematosus Patients on Belimumab
Michelle T. Ngo¹, Abigail Benitez², Kimberly J. Payne², Michael De Vera³, Terry Ann Milford² and Karina Marianne D. Torralba⁴, ¹Rheumatology, Loma Linda University, Loma Linda, CA, ²Loma Linda University, Loma Linda, CA, ³Transplant Surgery, Loma Linda University, Loma Linda, CA, ⁴Division of Rheumatology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA
Background/Purpose: The B cell pool is composed of subsets with different phenotypes and functions that mainly have effector functions to maintain immunologic tolerance. These…
Abstract Number: 1114 • 2015 ACR/ARHP Annual Meeting
Profiling Circulating Plasmablasts from Anti-Ro Positive Mothers of Children with Congenital Heart Block to Identify Antigenic Targets Conferring Pathogenicity
Sarah Kongpachith¹, WH Robinson¹, Sara Rasmussen², Robert Clancy³ and Jill P. Buyon³, ¹Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Neonatal lupus (NL) is an uncommon autoimmune disease classically manifest as permanent complete heart block and/or transient cutaneous lesions. By definition of NL, there…
Abstract Number: 1115 • 2015 ACR/ARHP Annual Meeting
B Cell-Intrinsic Interferon Gamma Signals Promote the Development of Systemic Lupus Erythematosus By Enhancing the Formation of Spontaneous Autoimmune Germinal Centers
Shaun Jackson, Nicole Scharping, Holly Jacobs, Tanvi Arkatkar, Socheath Khim and David Rawlings, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: Type 1 interferon (IFN) is strongly implicated in lupus pathogenesis, and SLE patients frequently express a “type 1 IFN gene signature”. The type 2…
Abstract Number: 1116 • 2015 ACR/ARHP Annual Meeting
Decreased Expression of Negative Regulators of Toll-like Receptor Signaling and Increased TLR7 Responsiveness in Expanded IgD- CD27- B Cells from Systemic Lupus Erythematosus Patients
Scott Jenks¹, Benjamin Barwick² and Ignacio Sanz³, ¹Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Emory University, Altanta, GA, ³Medicine, Emory University, Atlanta, GA
Background/Purpose: B cell homeostasis is perturbed in SLE patients; in particular many patients with active disease have a large expansion of IgD- CD27- B cells…
Abstract Number: 1117 • 2015 ACR/ARHP Annual Meeting
The B Cell Survival Cytokine BAFF Promotes Systemic Lupus Erythematosus Via Activation of TACI, Not BAFF Receptor
Holly Jacobs¹, Christopher Thouvenel¹, Tanvi Arkatkar¹, Nicole Scharping¹, David Rawlings² and Shaun Jackson¹, ¹Seattle Children's Research Institute, Seattle, WA, ²Pediatrics/Immunology, Washington, Seattle, WA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by polyclonal B cell activation and production of class-switched antinuclear antibodies (ANA). Transgenic mice…
Abstract Number: 1118 • 2015 ACR/ARHP Annual Meeting
Role of the Chemokine Receptor CXCR3 in the Function of Regulatory B Cells in Patients with SLE
Shun-ichiro Ota^1,2, Hiroaki Niiro³, Naoko Ueki^2,4, Yuri Hirosaki², Hirofumi Tsuzuki², Siamak Jabbarzadeh-Tabrizi², Tsuyoshi Nakayama², Koji Mishima², Ayako Takaki², Hiroki Mitoma², Mitsuteru Akahoshi², Yojiro Arinobu², Hiroshi Tsukamoto² and Koichi Akashi², ¹Department of Rheumatology, Internal medicine and connective tissue disorders, Shimonoseki City Hospital, Shimonoseki, Japan, ²Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, ³Clinical Education Center, Kyushu University Hospital, Fukuoka, Japan, ⁴Division of Nephrology and Rheumatology, Fukuoka University, Fukuoka, Japan
Background/Purpose: The emerging application of B-cell directed therapies in autoimmune diseases has led to the discovery of a novel B cell population, referred to as…
Abstract Number: 1119 • 2015 ACR/ARHP Annual Meeting
High Resolution Motif Mapping of in Situ Anti-Native-Vimentin Antibodies in Lupus Tubulointerstitial Nephritis
Andrew Kinloch¹, Yuta Asano², Balazs Banfai³, Gregor Dernick³, Carole Henry Dunand⁴, Nirit Mor-Vaknin⁵, Maureen Legendre⁵, David Markovitz⁵, Thomas Schindler⁶ and Marcus R. Clark⁷, ¹University of Chicago, Chicago, IL, ²Committee of immunology, University of Chicago, Chicago, IL, ³Translational Technologies and Bioinformatics, Roche, Basel, Switzerland, ⁴Rheumatology and Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁵University of Michigan, Ann Arbor, MI, ⁶Roche Innovation Center Basel, Roche, Basel, Switzerland, ⁷Rheumatology and Knapp Center for Lupus Research, University of Chicago, Chicago, IL
Background/Purpose: Severe lupus tubulointerstitial nephritis (TIN) is prognostic of renal failure and characterized by an in situ autoantibody response. By characterizing monoclonal antibodies engineered from…
Abstract Number: 1120 • 2015 ACR/ARHP Annual Meeting
Analysis of SLE Plasmablasts By High Throughput Pairing of the Immunoglobulin Heavy and Light Chain (VH-VL)
Deepak Tomar¹, Christopher Tipton¹ and Ignacio Sanz², ¹Medicine/Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: In-depth analysis of the molecular and antigenic properties of antibody secreting cells (ASC) is critical for our understanding of autoimmune diseases. This goal however…
Abstract Number: 1121 • 2015 ACR/ARHP Annual Meeting
Breach of B Cell Anergy in New Zealand Black Congenic Mice
Kieran Manion^1,2, Yuriy Baglaenko^1,2, Nan-Hua Chang³ and Joan Wither³, ¹Immunology, University of Toronto, Toronto, ON, Canada, ²Genetics and Development, Toronto Western Research Institute, University Health Network, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada
Background/Purpose: Anti-DNA B cells are a primary cause of pathology in individuals with systemic lupus erythematosus (SLE), producing autoantibodies that deposit in diverse tissues and…
Abstract Number: 1122 • 2015 ACR/ARHP Annual Meeting
B Cell Phenotypic Changes in Anti-Nuclear Antibody Positive Individuals Prior to the Onset of Systemic Autoimmune Rheumatic Disease
Joan Wither¹, Nan-Hua Chang¹, Babak Noamani², Dennisse Bonilla¹, Sindhu R. Johnson³, Larissa Lisnevskaia⁴, Earl Silverman⁵, Arthur Bookman¹ and Carolina Landolt-Marticorena¹, ¹University Health Network, Toronto, ON, Canada, ²Genetics and developmental biology, University Health Network, Toronto, ON, Canada, ³Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, ⁴Lakeridge Health Services, Oshawa, ON, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARD) often have a prolonged pre-clinical phase during which they are anti-nuclear antibody (ANA)+ but lack clinical symptoms. …
Abstract Number: 1123 • 2015 ACR/ARHP Annual Meeting
Regulatory B Cells Regulate Skin and Lung Fibrosis and Immunological Abnormalities in a Topoisomerase I and Complete Freund’s Adjuvant-Induced Scleroderma Model Via an Antigen-Specific Manner
Ayumi Yoshizaki¹, Takashi Taniguchi¹, Kouki Nakamura¹, Ryosuke Saigusa¹, Takashi Yamashita¹, Takehiro Takahashi¹, Tetsuo Toyama¹, Yohei Ichimura¹, Yoshihide Asano² and Shinichi Sato¹, ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Immune cells play a critical role in systemic sclerosis (SSc). B cells have more functions than producing antibodies, including antigen-presentation, various cytokine production, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].